Clinical Trial Update: Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

This clinical trial update reports on a Phase 2 study of bortezomib for unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Gastric Cancer | Phase 2 | Status: COMPLETED